Want to join the conversation?
$BIIB, global leader in the multiple sclerosis market, reported 4Q15 sales jump of 7.5% YoverY to $2.84Bil, driven by higher revenue from Tecfidera, Plegridy and Eloctate. For the quarter, net income attributable to $BIIB fell 5.8% to $831.6MM, or $3.77 per diluted share, compared with $883.5MM, or $3.74 per diluted share, a year ago.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.